← All organizations
Highest phase reached
Phase 3
First clinical trial
Sep 30, 2018Last known activity
Jun 3, 2024
Timeline
2010s
- Jul 1, 2017
Kartos Therapeutics, Inc.— Founded
Drugs by trial phase (9 distinct, 14 trials)
Phase 3 (2 own, 0 via acquisition)
Phase 2 (7 own, 0 via acquisition)
Indications
Studied for
- Carcinoma
- Carcinoma, Merkel Cell
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Myeloproliferative Disorders
- Polycythemia
- Polycythemia Vera
- Primary Myelofibrosis
- Thrombocythemia, Essential
- Thrombocytosis
Recent trials (16)
- NCT06479135Lead sponsorPhase 3Jun 3, 2024
- NCT05797831Lead sponsorPhase 2/Phase 3Jul 17, 2023
- NCT05705466Lead sponsorPhase 1/Phase 2Jun 30, 2023
- NCT05027867Lead sponsorPhase 2Nov 30, 2021
- NCT04835584Lead sponsorPhase 1/Phase 2May 7, 2021
- NCT04878003Lead sponsorPhase 2Apr 13, 2021
- NCT04669067CollaboratorPhase 1/Phase 2Feb 28, 2021
- NCT04485260Lead sponsorPhase 1/Phase 2Dec 31, 2020
- NCT04502394Lead sponsorPhase 1/Phase 2Dec 31, 2020
- NCT04640532Lead sponsorPhase 1/Phase 2Nov 17, 2020
- NCT04113616Lead sponsorPhase 1/Phase 2Sep 25, 2019
- NCT03787602Lead sponsorPhase 2May 31, 2019
- NCT03669965Study directorPhase 2Oct 31, 2018
- NCT03669965Lead sponsorPhase 2Oct 31, 2018
- NCT03662126Study directorPhase 2Sep 30, 2018
Details
- Founded
- Redwood City, CA, US Jul 1, 2017
- Last known activity
- Jun 3, 2024